Nantahala Capital Management, LLC - 17 Dec 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Reporting relationship: 10%+ Owner
Issuer ticker: EVOK
Reported as of: 17 Dec 2025
Net transaction value: -$12,001,796
SEC form: 4
Accepted by SEC: 19 Dec 2025, 16:15:35 UTC
Prior SEC filing: 09 Jun 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC

Key filing fact

Nantahala Capital Management, LLC filed Form 4 for Evoke Pharma Inc (EVOK) on 19 Dec 2025.

Key facts

This page summarizes Nantahala Capital Management, LLC's Form 4 filing for Evoke Pharma Inc (EVOK).
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 19 Dec 2025, 16:15.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: -$12,001,796.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001472322 Primary reporting owner

Nantahala Capital Management, LLC

Relationship: 10%+ Owner
Address: 130 MAIN ST. 2ND FLOOR, NEW CANAAN
Signature: /s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC
Signature date: 19 Dec 2025

CIK 0001775952

Harkey Wilmot B.

Relationship: 10%+ Owner
Address: 130 MAIN ST. 2ND FLOOR, NEW CANAAN
Signature: /s/ Wilmot B. Harkey
Signature date: 19 Dec 2025

CIK 0001775831

Mack Daniel

Relationship: 10%+ Owner
Address: 130 MAIN ST. 2ND FLOOR, NEW CANAAN
Signature: /s/ Daniel Mack
Signature date: 19 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVOK transaction

Common Stock

Other

Transaction value: $1,629,683
Shares: -148,153
Change %: -100%
Price: $11.00
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVOK transaction Derivative

Prefunded Warrants

Other

Transaction value: $4,773,148
Shares: -433,962
Change %: -100%
Price: $11.00
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 433,962
Exercise price: $0.000100
Footnotes: F1, F2

EVOK transaction Derivative

Series A Common Stock Purchase Warrants

Other

Transaction value: $551,159
Shares: -117,019
Change %: -100%
Price: $4.71
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 117,019
Exercise price: $8.16
Footnotes: F1, F2

EVOK transaction Derivative

Series C Common Stock Purchase Warrants

Other

Transaction value: $551,159
Shares: -117,019
Change %: -100%
Price: $4.71
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 117,019
Exercise price: $8.16
Footnotes: F1, F2

EVOK transaction Derivative

Amended Series A Common Stock Purchase Warrants

Other

Transaction value: $1,742,256
Shares: -158,531
Change %: -100%
Price: $10.99
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 158,531
Exercise price: $0.0100
Footnotes: F1, F2

EVOK transaction Derivative

Amended Series C Common Stock Purchase Warrants

Other

Transaction value: $2,754,391
Shares: -250,627
Change %: -100%
Price: $10.99
Shares after: 0
Date: 17 Dec 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 250,627
Exercise price: $0.0100
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Nantahala Capital Management, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.

Footnote F2

Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.